LFST vs ENSG

For growth investors, The Ensign Group, Inc.

(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus 13. 9% for LifeStance Health Group, Inc. (LFST). The Ensign Group, Inc. (ENSG) offers the better valuation at 29. 8x trailing P/E (23. 2x forward), making it the more compelling value choice. Analysts rate LifeStance Health Group, Inc. (LFST) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, The Ensign Group, Inc.

(ENSG) is the cheapest at 29. 8x versus LifeStance Health Group, Inc. at 442. 5x. On forward P/E, The Ensign Group, Inc. is actually cheaper at 23. 2x.

Over the past 5 years, The Ensign Group, Inc.

(ENSG) delivered a total return of +103. 2%, compared to -59. 6% for LifeStance Health Group, Inc. (LFST). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus LFST's -59. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Ensign Group, Inc.

(ENSG) is the lower-risk stock at 0. 42β versus LifeStance Health Group, Inc. 's 1. 20β — meaning LFST is approximately 183% more volatile than ENSG relative to the S&P 500. On balance sheet safety, LifeStance Health Group, Inc. (LFST) carries a lower debt/equity ratio of 13% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Ensign Group, Inc.

(ENSG) is pulling ahead at 18. 7% versus 13. 9% for LifeStance Health Group, Inc. (LFST). On earnings-per-share growth, the picture is similar: LifeStance Health Group, Inc. grew EPS 113. 3% year-over-year, compared to 14. 1% for The Ensign Group, Inc.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Ensign Group, Inc.

(ENSG) is the more profitable company, earning 6. 8% net margin versus 0. 7% for LifeStance Health Group, Inc. — meaning it keeps 6. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENSG leads at 8. 6% versus 1. 8% for LFST. At the gross margin level — before operating expenses — LFST leads at 28. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, The Ensign Group, Inc.

(ENSG) trades at 23. 2x forward P/E versus 121. 1x for LifeStance Health Group, Inc. — 97. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ENSG: 27. 6% to $222. 33.

In this comparison, ENSG (0.

1% yield) pays a dividend. LFST does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Ensign Group, Inc.

(ENSG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42), +752. 0% 10Y return). Both have compounded well over 10 years (ENSG: +752. 0%, LFST: -59. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LFST is a small-cap quality compounder stock; ENSG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.